Search Images Maps Play YouTube News Gmail Drive More »
Settings | Sign in

Clostridium difficile

VALNEVA Announces Successful Completion of Phase II for Clostridium Difficile Vaccine Candidate

GlobeNewswire (press release) - ‎Jul 25, 2016‎
Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva, commented, "We are pleased with the positive final data generated in this Phase II trial and believe that our C. difficile candidate has the potential to address a growing ...
See realtime coverage

FDA Delays Decision on Merck C. difficile Candidate, Seeks More Data

Genetic Engineering & Biotechnology News - ‎Jul 22, 2016‎
Merck & Co. said the FDA has delayed to October a decision on its application to market bezlotoxumab for the prevention of Clostridium difficile infection recurrence, after requesting more clinical data from the company. In a statement late yesterday ...

FDA grants QIDP for C. Difficile IV treatment

European Pharmaceutical Review - ‎Jul 25, 2016‎
Morphochem announced today that the U.S. Food and Drug Administration (FDA) has designated Morphochem's intravenous antibacterial product candidate MCB3837 as a qualified infectious disease product (QIDP) for the treatment of Clostridium difficile ...

Clostridium difficile Infection (CDI) Therapeutics Market Research Report Now Available at Research Corridor

The Republic of East Vancouver - ‎Jul 21, 2016‎
Research Corridor has published a new research study titled “Clostridium difficile Infection (CDI) Therapeutics Market - Growth, Share, Opportunities, Competitive Analysis and Forecast, 2015 - 2022”.

FDA issues QIDP, Fast Track designations to novel IV antibacterial for C. difficile infection

Healio - ‎Jul 26, 2016‎
The FDA has granted Qualified Infectious Disease Product and Fast Track designations to MCB3837, Morphochem's novel intravenous antibacterial candidate for treating Clostridium difficile infection, the manufacturer announced.

Clostridium difficile Infection (CDI) Therapeutic Market Research Report Now Available at Research Corridor

The Republic of East Vancouver - ‎Jul 14, 2016‎
Research Corridor has published a new research study titled “Clostridium difficile Infection (CDI) Therapeutic Market - Growth, Share, Opportunities, Competitive Analysis and Forecast, 2015 - 2022”.
See realtime coverage

VALNEVA : nouveaux résultats positifs pour son candidat vaccin contre le Clostridium difficile

Le Figaro - ‎Jul 25, 2016‎
(AOF) - Valneva a annoncé des résultats de fin de Phase II positifs pour son candidat vaccin prophylactique VLA84 visant la prévention primaire des infections au Clostridium difficile (CDI), actuellement l'une des principales causes mondiales d ...

Global Clostridium Difficile Partnering 2010 to 2016; New Report Launched

Digital Journal - ‎Jul 18, 2016‎
Bangalore, Karnataka -- (SBWIRE) -- 07/18/2016 -- Provides understanding and access to the clostridium difficile partnering deals and agreements entered into by the worlds leading healthcare companies.

FDA delays decision on Merck's C. diff drug

BioPharma Dive - ‎Jul 25, 2016‎
The Food and Drug Administration requested additional trial data and analysis for Merck's investigational monoclonal antibody, bezlotoxumab, which is in development for secondary prevention of Clostridium difficile (C. diff), the company reported Thursday.

2016 Global Clostridium difficile Partnering Market Research

NewsMaker (press release) - ‎Jul 21, 2016‎
RnRMarketResearch.com adds 'Global Clostridium difficile Partnering 2010 to 2016' Market Research to its database, providing in-depth, high quality, transparent and market-driven, expert's analysis.

Betsi Cadwaladr 'improvements' after C. diff outbreak

BBC News - ‎Jul 17, 2016‎
"Very significant improvements" have been made at a health board following the outbreak of a major infection three years ago.

Clostridium Difficile, slitta la registrazione Usa di bezlotoxumab

PharmaStar - ‎Jul 24, 2016‎
Clostridium Difficile, slitta la registrazione Usa di bezlotoxumab. L'Fda ha richiesto nuovi dati e nuove analisi degli studi MODIFY I e MODIFY II per poter prendere una decisione circa l'approvazione di bezlotoxumab, un nuovo anticorpo monoclonale ...

Does PPI Use Up Rate of Hospital-Acquired C. diff Infection?

Monthly Prescribing Reference (registration) - ‎Jul 25, 2016‎
The use of proton pump inhibitors (PPIs) was associated with an increase in both the rate and severity of hospital-acquired Clostridium difficile infection (CDI), according to a study published in Pharmacotherapy. Study authors performed a ...

WATCH: See how a superbug is created

STAT - ‎Jul 26, 2016‎
Some bacterial strains, such as Clostridium difficile and MRSA, are resistant to most, if not all, available antibiotics. article continues after advertisement.

Methods for More Accurate Microbiome Studies Could Impact Future Therapeutic Use

GenomeWeb - ‎18 hours ago‎
Gohl and Beckman noted there are a number of researchers pioneering fecal transplant, as well as companies - such as Seres, Rebiotix, and Assembly Bioscience - developing synthetic ecologies with the aim of displacing Clostridium difficile infections.

Poo Can Save Lives Thanks to New Fecal Transplant

Care2.com - ‎Jul 18, 2016‎
Fecal transplantation sounds gross and it's not something most of us want to talk about. But if you have a form of colitis called Clostridium difficile, someone else's fecal matter may cure what ails you. “There is no doubt that poo can save lives ...

Schneck Medical Center Implements the Power of Ultraviolet Technology against Hospital Infections

PR Newswire (press release) - ‎Jul 26, 2016‎
"Cleaning and disinfection plays a crucial role in infection prevention and with germs such as C. diff able to survive on surfaces for months at a time, we felt it was important to implement even more comprehensive cleaning procedures as part of our ...

Poop transplants are catching on again

Albuquerque Journal - ‎Jul 25, 2016‎
People who receive certain broad-spectrum antibiotics, such as clindamycin (Cleocin), sometimes end up with life-threatening diarrhea brought on by bacterial overgrowth from Clostridium difficile. The resulting C. diff colitis can be very hard to treat ...

Autism and the Microbiome: Will Fecal Transplants Be the Next “AWAKENINGS?" Part 2

Age of Autism - ‎Jul 25, 2016‎
Fecal microbiota transplantation (FMT), a unique method to reestablish a sustained balance in the disrupted microbiota of diseased intestine, has demonstrated great success in the treatment of recurrent Clostridium difficile infection and has gained ...
 -